



# Differentiating clearly

HELPS YOU MAKE  
INFORMED DECISIONS

miRview™  
meso

TAKE a closer look WITH

**miRview™** meso

*Accurately differentiates malignant  
pleural mesothelioma from other  
carcinomas in the lung and pleura*

## Clinical impact: make an *accurate* diagnosis of malignant pleural mesothelioma

### Differential diagnosis of malignant pleural mesothelioma is critical

- It is important to rule out mesothelioma in patients with lung adenocarcinoma and other carcinomas in the lung and pleura who have been exposed to mesothelioma-related substances.<sup>1</sup>
  - Clinical presentation may be misleading and adversely affect treatment selection.<sup>1</sup>
- Optimal therapy depends on an accurate, specific diagnosis.
- Mesothelioma patients require specific treatment regimens.<sup>2</sup>
  - Malignant mesothelioma often responds poorly to radiation, and surgery may not be an option due to its invasive nature.<sup>2</sup>
  - Chemotherapy is the preferred therapeutic option, but proven regimens remain unidentified, and novel agents are being explored.<sup>2</sup>

## Clinical challenge: accurately differentiate malignant pleural mesothelioma from other carcinomas in the lung and pleura

### Similar presentation makes mesothelioma difficult to distinguish from other malignancies

- Until now, there has been no single, conclusive test for either malignant mesothelioma or metastatic tumors.<sup>3,4</sup>
  - Primary lung carcinomas frequently involve the lung pleura, and several other cancers metastasize to the lung.
  - Pathological diagnosis is confounded by significant interobserver variability.<sup>5</sup>
- In the absence of specific clinical biomarkers, mesothelioma can be difficult to differentiate from other malignancies.<sup>6</sup>
  - Even recently developed antibody panels do not demonstrate routine success.<sup>7,8</sup>

Take a closer look with miRview™ meso


## Introducing a sensitive and accurate diagnostic tool—miRview™ meso

### A state-of-the-art molecular diagnostic test that differentiates mesothelioma from other carcinomas in the lung and pleura with:

- Accuracy
- Speed
- Simple interpretation
- Quantitative analysis
- Objective results
- Cutting-edge molecular biology

### Using microRNA profiling will help<sup>6</sup>:

- Ensure accurate differential diagnoses
- Rule out mesothelioma in patients diagnosed with carcinomas in the lung and pleura
- Provide diagnostic information to optimize treatment plans



## Validation ensures quality results

### Test description

The miRview™ meso assay uses quantitative real-time PCR (qRT-PCR) to determine the expression of microRNA in tumor tissue.

### Interpretation of results

The diagnosis is based on two scores, which represent the expression level of three microRNA biomarkers.

- For scores 1 and 2, a higher score is interpreted as stronger evidence of mesothelioma.
- The test outcome is “mesothelioma” when both scores are greater than zero.
- Otherwise, the test outcome is “non-mesothelioma.”
- Validated assay:
  - The sensitivity and specificity of this assay were 95% and 96%, respectively.<sup>9</sup>

## Routine sample preparation

- miRview™ meso is based on formalin-fixed, paraffin-embedded (FFPE) tumor samples—the standard for preserving tumor samples.

**ROSETTA**  
GENOMICS

## miRview™ meso: know the difference

- Accurately diagnose mesothelioma for the best opportunity to optimize treatment plans.
- Avoid the risks of inconclusive diagnostic techniques.
- Use miRview™ meso, a microRNA-based molecular diagnostic test that provides a differential diagnosis with:
  - Accuracy
  - Simple interpretation
  - Easy sample preparation

miRview™ meso is a microRNA-based molecular diagnostic test that differentiates malignant pleural mesothelioma from peripheral adenocarcinomas of the lung or metastatic carcinomas involving the lung pleura

Call Rosetta Genomics Customer Support toll-free to request a Collection Kit at **888-522-7971**.

Visit us online at [www.mirviewdx.com](http://www.mirviewdx.com) for more information.



#### REFERENCES

1. Asbestosis mesothelioma information and resource guide. <http://www.asbestosismesothelioma.com>. Accessed February 9, 2009.
2. Palumbo C, Bei R, Procopio A, Modesti A. Molecular targets and targeted therapies for malignant mesothelioma. *Curr Med Chem*. 2008;15(9):855-867.
3. Klebe S, Mahar A, Henderson DW, Roggli VL. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. *Mod Pathol*. 2008;21(9):1084-1094.
4. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. *Nat Biotechnol*. 2008;26(4):462-469.
5. Stang A, Pohlabein H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. *Lung Cancer*. 2006;52(1):29-36.
6. Benjamin H, Lebanony D, Cohen L, et al. Differential diagnosis of mesothelioma using a microRNA assay. Presented at: 44th American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2008; Chicago, IL. Abstract 22000.
7. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. *Arch Pathol Lab Med*. 2008;132(3):397-401.
8. Yaziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. *Mod Pathol*. 2006;19(4):514-523.
9. Data on file, Rosetta Genomics.

miRview™ meso